
## Julian Carretero

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1086291/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors. Cancer Discovery, 2013, 3, 1355-1363.	7.7	1,073
2	Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor. Cancer Cell, 2014, 26, 909-922.	7.7	376
3	Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radical Biology and Medicine, 2002, 33, 387-398.	1.3	338
4	Integrative Genomic and Proteomic Analyses Identify Targets for Lkb1-Deficient Metastatic Lung Tumors. Cancer Cell, 2010, 17, 547-559.	7.7	215
5	Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by <i>EML4-ALK</i> Fusion Oncogene. Cancer Research, 2010, 70, 9827-9836.	0.4	181
6	Changes in glutathione status and the antioxidant system in blood and in cancer cells associate with tumour growth in vivo. Free Radical Biology and Medicine, 1999, 26, 410-418.	1.3	180
7	Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research, 2013, 19, 6183-6192.	3.2	179
8	Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade. Journal of Thoracic Oncology, 2017, 12, 1268-1279.	0.5	152
9	Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer. Clinical Cancer Research, 2012, 18, 4973-4985.	3.2	141
10	Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. Oncogene, 2007, 26, 1616-1625.	2.6	130
11	HIF2α cooperates with RAS to promote lung tumorigenesis in mice. Journal of Clinical Investigation, 2009, 119, 2160-2170.	3.9	129
12	Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress. Hepatology, 2004, 39, 711-720.	3.6	127
13	Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a Target in <i>LKB1</i> -Mutant Lung Cancer. Cancer Discovery, 2013, 3, 870-879.	7.7	127
14	Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 8699-8704.	3.3	114
15	Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene. Oncogene, 2004, 23, 4037-4040.	2.6	111
16	Intratumoral Heterogeneity in <i>EGFR</i> -Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition. Cancer Research, 2015, 75, 4372-4383.	0.4	108
17	Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer. Cancer Discovery, 2016, 6, 1006-1021.	7.7	108
18	Genetic and Epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors, Genes Chromosomes and Cancer, 2004, 41, 170-177.	1.5	103

JULIAN CARRETERO

#	Article	IF	CITATIONS
19	Growth-associated changes in glutathione content correlate with liver metastatic activity of B16 melanoma cells. Clinical and Experimental Metastasis, 1999, 17, 567-574.	1.7	99
20	Acceleration of Glutathione Efflux and Inhibition of Î <sup>3</sup> -Glutamyltranspeptidase Sensitize Metastatic B16 Melanoma Cells to Endothelium-induced Cytotoxicity. Journal of Biological Chemistry, 2005, 280, 6950-6959.	1.6	82
21	γ-Clutamyl transpeptidase overexpression increases metastatic growth of B16 melanoma cells in the mouse liver. Hepatology, 2002, 35, 74-81.	3.6	81
22	Natural polyphenols facilitate elimination of HT-29 colorectal cancer xenografts by chemoradiotherapy: a Bcl-2- and superoxide dismutase 2-dependent mechanism. Molecular Cancer Therapeutics, 2008, 7, 3330-3342.	1.9	81
23	β-Catenin Contributes to Lung Tumor Development Induced by EGFR Mutations. Cancer Research, 2014, 74, 5891-5902.	0.4	76
24	Novel Transcriptional Targets of the SRY-HMG Box Transcription Factor SOX4 Link Its Expression to the Development of Small Cell Lung Cancer. Cancer Research, 2012, 72, 176-186.	0.4	73
25	D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes and Development, 2014, 28, 479-490.	2.7	70
26	Bcl-2 and Glutathione Depletion Sensitizes B16 Melanoma to Combination Therapy and Eliminates Metastatic Disease. Clinical Cancer Research, 2007, 13, 2658-2666.	3.2	68
27	Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition. Clinical Cancer Research, 2017, 23, 3203-3213.	3.2	66
28	Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition. Clinical Cancer Research, 2017, 23, 3203-3213.	3.2	66
29	Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro. PLoS ONE, 2020, 15, e0228909.	1.1	66
30	PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data. Genome Medicine, 2018, 10, 41.	3.6	63
31	Distinctive gene expression of human lung adenocarcinomas carrying LKB1 mutations. Oncogene, 2004, 23, 5084-5091.	2.6	61
32	Transcriptional targets of the chromatin-remodelling factor SMARCA4/BRG1 in lung cancer cells. Human Molecular Genetics, 2005, 14, 973-982.	1.4	55
33	Tumoricidal Activity of Endothelial Cells. Journal of Biological Chemistry, 2001, 276, 25775-25782.	1.6	47
34	Tumor Cytotoxicity by Endothelial Cells. Journal of Biological Chemistry, 2003, 278, 13888-13897.	1.6	44
35	<i>PARD3</i> Inactivation in Lung Squamous Cell Carcinomas Impairs STAT3 and Promotes Malignant Invasion. Cancer Research, 2015, 75, 1287-1297.	0.4	44
36	CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC. Cancer Research, 2019, 79, 4439-4452.	0.4	44

JULIAN CARRETERO

#	Article	IF	CITATIONS
37	Down-regulation of Glutathione and Bcl-2 Synthesis in Mouse B16 Melanoma Cells Avoids Their Survival during Interaction with the Vascular Endothelium. Journal of Biological Chemistry, 2003, 278, 39591-39599.	1.6	42
38	Bcl-2 and Mn-SOD Antisense Oligodeoxynucleotides and a Glutamine-enriched Diet Facilitate Elimination of Highly Resistant B16 Melanoma Cells by Tumor Necrosis Factor-α and Chemotherapy. Journal of Biological Chemistry, 2006, 281, 69-79.	1.6	40
39	Mitochondrial glutathione depletion by glutamine in growing tumor cells. Free Radical Biology and Medicine, 2000, 29, 913-923.	1.3	38
40	Glutamine potentiates TNF-α-induced tumor cytotoxicity. Free Radical Biology and Medicine, 2001, 31, 642-650.	1.3	36
41	De novo lipogenesis represents a therapeutic target in mutant Kras nonâ€small cell lung cancer. FASEB Journal, 2018, 32, 7018-7027.	0.2	33
42	LipidMS: An R Package for Lipid Annotation in Untargeted Liquid Chromatography-Data Independent Acquisition-Mass Spectrometry Lipidomics. Analytical Chemistry, 2019, 91, 836-845.	3.2	33
43	Temporal Molecular and Biological Assessment of an Erlotinib-Resistant Lung Adenocarcinoma Model Reveals Markers of Tumor Progression and Treatment Response. Cancer Research, 2012, 72, 5921-5933.	0.4	31
44	Expression inactivation of SMARCA4 by microRNAs in lung tumors. Human Molecular Genetics, 2015, 24, 1400-1409.	1.4	26
45	Abstract B290: Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors , 2013, , .		26
46	Loss of p53 Attenuates the Contribution of IL-6 Deletion on Suppressed Tumor Progression and Extended Survival in Kras-Driven Murine Lung Cancer. PLoS ONE, 2013, 8, e80885.	1.1	23
47	Possible Mechanisms for Tumour Cell Sensitivity to TNF-a and Potential Therapeutic Applications. Current Pharmaceutical Biotechnology, 2001, 2, 119-130.	0.9	17
48	Tumoricidal activity of endothelium-derived NO and the survival of metastatic cells with high GSH and Bcl-2 levels. Nitric Oxide - Biology and Chemistry, 2008, 19, 107-114.	1.2	15
49	Endothelin-1–Mediated Drug Resistance in <i>EGFR</i> -Mutant Non-Small Cell Lung Carcinoma. Cancer Research, 2020, 80, 4224-4232.	0.4	12
50	Comprehensive Analysis of SWI/SNF Inactivation in Lung Adenocarcinoma Cell Models. Cancers, 2020, 12, 3712.	1.7	6
51	Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor. Cancer Cell, 2015, 27, 149.	7.7	3
52	A role for the 2-oxoglutarate carrier in glutathione transport into hepatocyte mitochondria?. Hepatology, 2004, 39, 570-571.	3.6	2
53	A Very Rare Variant in SREBF2, a Possible Cause of Hypercholesterolemia and Increased Glycemic Levels. Biomedicines, 2022, 10, 1178.	1.4	2
54	ETS-1 Regulates Twist-1 Expression In Non-Small Cell Lung Cancer (NSCLC) Progression And Metastasis. , 2011, , .		1

JULIAN CARRETERO

#	Article	IF	CITATIONS
55	Srebf2 Locus Overexpression Reduces Body Weight, Total Cholesterol and Glucose Levels in Mice Fed with Two Different Diets. Nutrients, 2020, 12, 3130.	1.7	1
56	Epigenetics and precision medicine in lung cancer. , 2022, , 109-145.		1
57	Increased Ets-1 Positively Correlates With Twist1 Expression In Mouse Non-small Cell Lung Cancer (NSCLC) Progression And Metastases. , 2010, , .		0
58	Abstract A292: Salinomycin, an anti-cancer stem cell antibiotic, overcomes acquired resistance to BRAF inhibitors inBRAF-mutant human melanoma cell lines , 2013, , .		0
59	Abstract 968: β-catenin plays an important role in lung tumor development induced by EGFR mutations. , 2014, , .		0
60	Abstract 3940: Inactivation of the PARD3 gene is a recurrent event in lung squamous cell carcinomas and affects STAT3 activity and tumor invasiveness. , 2015, , .		0
61	Abstract 753: Genomic alterations of autophagy genes disrupts autophagic flux in human lung adenocarcinomas. , 2015, , .		0
62	Abstract 766: Suppression of gefitinib-induced EMT in EGFR mutant NSCLC preferentially selects for acquired T790M. , 2015, , .		0
63	Abstract 4479: Unveiling the relationship between the SWI/SNF chromatin remodeling complex and noncoding RNAs. , 2016, , .		0
64	Baseline circulating myeloid-derived suppressor cells subpopulations, neutrophils/lymphocytes ratio, and response to PD-1/PD-L1 inhibitor in non-small cell lung cancer patients Journal of Clinical Oncology, 2020, 38, e15042-e15042.	0.8	0